IBM's Watson to Guide Cancer Therapies at 14 Centers

(MedPage Today) -- "Humans alone can't do it," oncologist says.
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news

Related Links:

Publication date: Available online 19 March 2019Source: European Journal of Integrative MedicineAuthor(s): Shiao Li Oei, Anja Thronicke, Matthias Kröz, Cornelia Herbstreit, Friedemann SchadAbstractIntroductionViscum album L. extracts (VA) are frequently used in integrative oncology to enhance health-related quality of life. As a central aspect of well-being is associated with feeling warm or cold the internal coherence scale (ICS) questionnaire including the thermo coherence measurement was utilized.MethodsA prospective observational longitudinal cohort study was conducted, using data from the Network Oncology clinica...
Source: European Journal of Integrative Medicine - Category: Complementary Medicine Source Type: research
Publication date: 18 March 2019Source: Cancer Cell, Volume 35, Issue 3Author(s): Niamh McDermott, Erika S. Buechelmaier, Simon N. PowellTumors resistant to PARP inhibitors frequently show signs of replication stress, with hyper-activated PARP. In this issue of Cancer Cell, Pillay et al. demonstrate that inhibiting PAR-chain turnover results in cell-cycle arrest, which is cytotoxic when combined with cell-cycle checkpoint inhibition and constitutes a novel cancer therapy.
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research
Authors: Wu H, Jiang W, Li B, Yang H, Zhao X, Zhang H, Wang S, Peng L, Wang L, Wang X, Dai G, Fang C Abstract The expression of leucine aminopeptidase 3 (LAP3) is associated with the prognosis for and malignant transformation of many types of tumors. Therefore, a LAP3 inhibitor may represent a new strategy for cancer therapy. Evaluating the suppression of enzyme activity by an LAP3 inhibitor is essential. Right now, leucine aminopeptidases (LAPs) purified from the porcine kidneys are the only enzymes that can be used to evaluate the suppression of enzyme activity by an LAP3 inhibitor. This approach cannot accuratel...
Source: Drug Discoveries and Therapeutics - Category: Drugs & Pharmacology Tags: Drug Discov Ther Source Type: research
fellner Antibody-drug conjugates (ADCs) combine the tumor selectivity of antibodies with the potency of cytotoxic small molecules thereby constituting antibody-mediated chemotherapy. As this inherently limits the adverse effects of the chemotherapeutic, such approaches are heavily pursued by pharma and biotech companies and have resulted in four FDA (Food and Drug Administration)-approved ADCs. However, as with other cancer therapies, durable responses are limited by the fact that under cell stress exerted by these drugs, tumors can acquire mechanisms of escape. Resistance can develop against the antibody component of ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
In this study, a series of chalcone derivatives was screened by in vitro cytotoxicity against the wild type (A431 and A549) and mutant EGFR (H1975 and H1650) cancer cell lines, and, subsequently, tested for EGFR-tyrosine kinase (TK) inhibition. From the experimental screening, all chalcones seemed to be more active against the A431 than the A549 cell line, with chalcones 1c, 2a, 3e, 4e, and 4t showing a more than 50% inhibitory activity against the EGFR-TK activity and a high cytotoxicity with IC50 values of < 10 µM against A431 cells. Moreover, these five chalcones showed more potent on H1975 (T790M/L858R...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
New J. Chem., 2019, Accepted Manuscript DOI: 10.1039/C9NJ00263D, PaperDong Xu, Muhammad A Tahir, Liwu Zhang, Christian G. Sch äfer Here we report a straight forward synthetic procedure for the preparation of metal-containing polymer microspheres with combined magnetic resonance imaging (MRI) as well as controlled anti-cancer drug release functionality confined... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - New J. Chem. latest articles - Category: Chemistry Authors: Source Type: research
acute;gyi T Abstract Tyrosine kinases play crucial roles in cellular development and tumorigenesis. Tyrosine kinase inhibitors (TKIs) are effective and widely used drug molecules in targeted cancer therapies. Altered expressions of protooncogenes and tumor suppressor genes after DMBA (7,12-dimethylbenz[a]anthracene) treatment have been described as early markers of tumor induction; however their tissue-specific effects remain still unclear. Our study was aimed at examining the short-term possible antineoplastic and chemopreventive effects of a TKI compound (imatinib mesylate) on a DMBA-induced mouse tumor model. I...
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
This article reviews survivorship considerations, with particular attention paid to the physical, psychosocial, and financial effects for adults who have undergone CAR T-cell therapy. METHODS: A review of the physiologic and psychosocial sequelae resulting from CAR T-cell therapy is presented, with a focus on late effects and financial toxicities of treatment. Physiologic concerns include B-cell aplasia and resulting hypogammaglobulinemia, as well as prolonged cytopenias and associated risk for infection. FINDINGS: To date, adult CAR T-cell therapy survivorship data are limited. However, data from clinical trials...
Source: Clinical Journal of Oncology Nursing - Category: Nursing Authors: Tags: Clin J Oncol Nurs Source Type: research
(MedPage Today) -- Patient preference assessment tool aligns with pros and cons of prostate cancer therapies
Source: MedPage Today Primary Care - Category: Primary Care Source Type: news
Abstract: Genomic analyses in oncologic care allow for the development of more precise clinical laboratory tests that will be critical for personalized pharmacotherapy. Traditional biopsy-based approaches are limited by the availability of sequential tissue specimens to detect resistance. Blood-based genomic profiling (“liquid biopsy”) is useful for longitudinal monitoring of tumor genomes and can complement biopsies. Tumor-associated mutations can be identified in cell-free tumor DNA (ctDNA) from patient blood samples and used for monitoring disease activity. The US Food and Drug Administration approved a li...
Source: Therapeutic Drug Monitoring - Category: Drugs & Pharmacology Tags: Review Articles: Focus on Pharmacodynamic Drug Monitoring Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Hematology